<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02058459</url>
  </required_header>
  <id_info>
    <org_study_id>AIRFLOW</org_study_id>
    <nct_id>NCT02058459</nct_id>
  </id_info>
  <brief_title>Targeted Lung Denervation for Patients With Moderate to Severe COPD</brief_title>
  <acronym>AIRFLOW</acronym>
  <official_title>A Sequential Two Phase Multicenter, Randomized Study to Optimize Dose Selection and Evaluate Safety After Treatment With the Holaira™ Lung Denervation System in Patients With Moderate to Severe COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuvaira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nuvaira, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety of Targeted Lung Denervation (or TLD) in
      patients suffering from moderate to severe COPD. It is hypothesized that TLD will have a
      similar safety profile and improved physiological and functional outcomes to a sham-control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, sequential two phase multicenter, randomized double-blind, safety, &amp;
      feasibility study. The goal of AIRFLOW-1 will be to compare two energy doses and select the
      optimal energy dose to be utilized in AIRFLOW-2. The goal of AIRFLOW-2 is to compare the
      optimal energy dose to a sham control. All subjects will be followed for a minimum of 3
      years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AIRFLOW-1: Therapeutic interventions through 3 months; AIRFLOW-2: and rate of respiratory adverse events between 3 and 6.5 months</measure>
    <time_frame>3-6.5 months</time_frame>
    <description>Respiratory adverse events is defined as: worsening bronchitis, worsening dyspnea, common cold, COPD exacerbation, influenza, pneumonia, respiratory infection, respiratory failure, tachypnea and wheezing. Subjects may have reported more than one type of respiratory adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events over 3 years</measure>
    <time_frame>3 years</time_frame>
    <description>The assessment of safety will be based on reporting of adverse events, particularly those adverse events that are respiratory in origin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>6 months</time_frame>
    <description>Device success is defined as ability to deliver the test device to its intended locations, provide complete circumferential treatment and removal of the test device without the report of an adverse event during the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry measures</measure>
    <time_frame>3 years</time_frame>
    <description>Measures include: FEV1, FVC, FEV1/FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional testing: Cycle Ergometry &amp; 6MWT</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heath-related Quality of Life (SGRQ-C &amp; EQ-5D)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>Through discharge</time_frame>
    <description>Procedure Success is defined as device success without the report of an adverse event through hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plethysmography measures</measure>
    <time_frame>3 years</time_frame>
    <description>Measures include Raw, TLC, IC, ITGW</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT Scan assessment</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Targeted Lung Denervation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active targeted lung denervation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham-Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>non-active targeted lung denervation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holaira™ Lung Denervation System with energy delivery</intervention_name>
    <arm_group_label>Targeted Lung Denervation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holaira™ Lung Denervation System without energy delivery</intervention_name>
    <arm_group_label>Sham-Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD with 30% ≤ FEV1 &lt; 60% and FEV1/FVC &lt;70% (post-bronchodilator);

          -  Patient ≥ 40 and ≤ 75 years of age at the time of consent;

          -  The patient has no child bearing potential or a negative pregnancy test (serum or
             urine), if applicable;

          -  Smoking history of at least 10 pack years;

          -  Non-smoking for a minimum of 2 months prior to consent and agrees to continue not
             smoking for the duration of the study;

          -  Participated in a pulmonary rehabilitation program or engaged in regular physical
             activity under professional supervision in the past 12 months;

        Exclusion Criteria:

          -  Has been less than 6 weeks following the resolution of a COPD exacerbation or active
             lower respiratory infection (eg. pneumonia);

          -  History of recurrent respiratory infections and/or COPD exacerbations (more than 2
             hospitalizations within 1 year of enrollment);

          -  Prior lung or chest procedure (eg. lung transplant, LVRS, BLVR, lung implant, metal
             stent, valves, coils, median sternotomy, bullectomy, segmentectomy, or lobectomy);

          -  Documented history of asthma diagnosed with onset &lt;30 years of age, cystic fibrosis,
             paradoxical vocal cord motion, Churg-Strauss syndrome, allergic bronchopulmonary
             aspergillosis, severe interstitial lung disease or active tuberculosis;

          -  Pulmonary nodule requiring follow-up or intervention unless proven benign;

          -  Daily use of &gt;10 mg of prednisone or its equivalent at the time of enrollment;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk-Jan Slebos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arschang Valipour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Otto-Wagner-Spital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKH Allgemeines Krankenhaus der Stadt Linz GmbH</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-Wagner-Spital</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Paris - Hopital Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite-Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik - West German Lung Center</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios-Fachkliniken</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikverbund Kempten-Oberallgaeu</name>
      <address>
        <city>Kempten</city>
        <zip>87509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtity Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <state>The Netherlands</state>
        <zip>9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton</name>
      <address>
        <city>London</city>
        <zip>SW3,6NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2014</study_first_submitted>
  <study_first_submitted_qc>February 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2014</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease, targeted lung denervation, intervention, device, safety, lung function, Holaira</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

